جست‌وجوی استاد و پژوهشگر

Joseph Buxbaumمشاهده پروفایل

استاد

• Autism Spectrum Disorder
• Alzheimer's Disease
• Schizophrenia
• +۷ مورد دیگر

Joseph Buxbaum serves as Professor of Psychiatry at Icahn School of Medicine at Mount Sinai and Director of the Seaver Autism Center for Research and Treatment. His academic appointments span multiple institutes including the Friedman Brain Institute, Genetics and Genomic Sciences, and the Mindich Child Health and Development Institute, reflecting his interdisciplinary research approach. Dr. Buxbaum's research focuses on the genetic and molecular mechanisms underlying neurodevelopmental and psychiatric disorders. His laboratory investigates autism spectrum disorder through genetic mapping and functional characterization of susceptibility genes like SHANK2 and AGC1. In schizophrenia research, his team pioneered the oligodendrocyte dysfunction hypothesis based on microarray studies. For Alzheimer's disease, they examine amyloid precursor protein signaling pathways and calsenin function in amyloid processing. His publication record demonstrates sustained productivity with 493 research outputs including over 400 articles. Recent work shows continued high output with 16 publications in 2023 and multiple 2024-2025 publications in high-impact journals. Analysis of his recent articles reveals strong emphasis on genomic approaches to autism, OCD, and dementia, with particular focus on rare variants, cross-disorder analyses, and functional validation. Dr. Buxbaum's scientific impact is evidenced by his h-index of 132 and 85,766 citations. While specific awards aren't listed in the source material, his leadership of the Seaver Autism Center and participation in major genomic consortia indicate significant recognition in the field. As director of the Laboratory of Molecular Neuropsychiatry, he mentors trainees in molecular analysis of neurological diseases using state-of-the-art techniques. His lab maintains active collaborations through the Trans-Ancestry OCD Genomics Initiative, Alzheimer's Disease Genetics Consortium, and international autism research networks. Current research leverages genomic sequencing, animal models, and stem cell technologies to advance understanding of neurodevelopmental disorders.

• Alzheimer's Disease Research
• Neurodegeneration
• Amyloid-beta
• +۶ مورد دیگر

Richard Cowburn is an Associate Professor in Neurobiology and currently serves as Head of Unit in Joint Operational Support at Karolinska Institutet. With a career spanning over three decades in Alzheimer's disease research, he maintains an active role in both academic research and research administration. His position within the Department for Research Support and External Relations, specifically in the External Engagement Office, reflects his dual expertise in neuroscience and research management. Dr. Cowburn's research has consistently focused on the molecular mechanisms underlying Alzheimer's disease, with particular emphasis on amyloid-beta processing, tau phosphorylation, presenilin function, and associated signal transduction pathways. His work has significantly contributed to understanding how disruptions in calcium homeostasis, protein kinase signaling, and oxidative stress contribute to neurodegeneration. Analysis of his publication record from 2006-2015 reveals a sustained focus on the intersection of protein processing, cellular signaling, and neurodegeneration. His research increasingly explored connections between Alzheimer's and Parkinson's disease mechanisms, particularly regarding protein homeostasis and mitochondrial function. Notably, his work on γ-secretase modulators and amyloid-beta cleaving enzyme inhibitors represents direct pathways toward developing Alzheimer's treatments. As Head of Unit responsible for business collaboration, Dr. Cowburn plays a crucial role in facilitating research partnerships between Karolinska Institutet and external organizations. His extensive publication history and expertise in neurodegenerative disease mechanisms position him as a valuable resource for both academic research and translational initiatives.

• Cancer Metabolism
• Breast Cancer
• Neurodegenerative Diseases
• +۳ مورد دیگر

Dr. Annika Glotzbach is a Scientific Associate in the Cell Metabolism team at the Leibniz Research Centre for Working Environment and Human Factors (IfADo) in Dortmund, Germany, conducting research within the Toxicology department. Her work focuses on molecular mechanisms in cancer metabolism and neurodegenerative diseases, with direct collaboration under Prof. Dr. Jan G. Hengstler. Her primary research interests center on breast cancer metabolism, particularly in ER-HER2+ subtypes, investigating how lipid storage and glycerophosphodiesterases like EDI3 and LIPG influence tumor progression, therapy resistance, and metastasis. She also explores Alzheimer's disease pathogenesis through APP intracellular domain signaling pathways, bridging cancer biology and neurodegeneration research. Recent publications reveal consistent trends in targeting metabolic adaptations in cancer cells, with 2023-2024 studies demonstrating EDI3's role in HER2 therapy resistance and metastasis, while her 2019 work established LIPG's function in oxidative stress adaptation. These studies employ mouse models and molecular techniques to identify therapeutic vulnerabilities in breast cancer. No information regarding student advising or research grants was found in the provided text. Dr. Glotzbach operates within the Cell Metabolism team at IfADo, which maintains strong institutional ties with the Technical University of Dortmund and participates in collaborative projects across the Leibniz Association network, utilizing core facilities including bioimaging and intravital toxicology units.